Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function

J Bras Nefrol. 2020 Aug 26;42(2 suppl 1):49-50. doi: 10.1590/2175-8239-JBN-2020-S113.
[Article in English, Portuguese]

Abstract
in English, Portuguese

Chloroquine and hydroxychloroquine have shown promising preliminary results and have been discussed as therapeutic options for patients with Covid-19. Despite the lack of robust evidence demonstrating the benefits and justifying the use of one of these drugs, the final decision is the responsibility of the attending physician and should be individualized and shared, whenever possible. This position statement recommends dosage adjustment for these drugs in the context of renal impairment.

Em razão de resultados preliminares promissores, a hidroxicloroquina e a cloroquina têm sido discutidas como opção terapêutica para pacientes com Covid-19. Apesar da ausência de estudos robustos que evidenciem o benefício e justifiquem o uso de uma dessas drogas, a decisão final compete ao médico assistente, devendo ser individualizada e, sempre que possível, compartilhada. A presente nota pretende orientar o ajuste posológico dessas drogas no contexto da disfunção renal.

Publication types

  • Practice Guideline

MeSH terms

  • Antimalarials / administration & dosage*
  • Brazil
  • COVID-19
  • COVID-19 Drug Treatment
  • Chloroquine / administration & dosage*
  • Coronavirus Infections / drug therapy*
  • Humans
  • Hydroxychloroquine / administration & dosage*
  • Nephrology
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Renal Insufficiency*
  • Societies, Medical

Substances

  • Antimalarials
  • Hydroxychloroquine
  • Chloroquine